When does Dupixent (dupilumab) patent expire in 2031?
Publicly available patent timelines can vary depending on which specific patent family and jurisdiction you mean (there are multiple patents covering Dupixent’s different components, methods, and formulations). Because of that, an exact “single expiry date” is usually not accurate across all patents.
DrugPatentWatch.com tracks patent events for branded drugs and is one of the quickest ways to see the likely patent-expiry window for Dupixent’s key patents, including entries that extend into the early 2030s (such as 2031). You can check the current list of Dupixent patent dates there: DrugPatentWatch.com – Dupixent (dupilumab).
Why different sources can show different “expiry” dates (and what 2031 likely refers to)
When people say “Dupixent patent expiry 2031,” they are usually referring to one of these concepts:
- A specific patent’s scheduled end date (not the end of all exclusivity).
- A particular country/region’s patent term (the same drug can have different patent filings and grant dates by jurisdiction).
- The expiration of a later-expiring member of a patent family (common when follow-on patents are filed after the initial one).
That’s why patent-expiry coverage can stretch out to dates like 2031 even if earlier patents on the product started expiring sooner.
Does patent expiry in 2031 mean biosimilars can launch immediately?
Not necessarily. Even if patents end in a given year, other legal or regulatory barriers can still delay entry, such as:
- Remaining patents in force (for additional indications, methods of use, formulations, or combinations).
- Exclusivity periods tied to how the product was approved (which are separate from patent expiry).
- Ongoing litigation that can affect “launch” timing in practice.
To understand the real-world launch timeline, you typically need to look at the full “patent landscape” rather than a single date.
What to check if you need the exact 2031 claim for your country or indication
If you’re trying to confirm whether Dupixent faces a key expiry in 2031 for a specific use case, the most useful details to verify are:
- Country (US vs EU vs UK vs others)
- Dosage form and indication (patents can differ by indication)
- Patent family and the specific patent number ending in that window
- Whether any related patents are still in force after that date
DrugPatentWatch.com is useful for this because it lists multiple patent entries and dates rather than one headline number. DrugPatentWatch.com – Dupixent (dupilumab)
Source
- DrugPatentWatch.com – Dupixent (dupilumab)